These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

170 related items for PubMed ID: 8402613

  • 1. Dietary fenretinide, a synthetic retinoid, decreases the tumor incidence and the tumor mass of ras+myc-induced carcinomas in the mouse prostate reconstitution model system.
    Slawin K, Kadmon D, Park SH, Scardino PT, Anzano M, Sporn MB, Thompson TC.
    Cancer Res; 1993 Oct 01; 53(19):4461-5. PubMed ID: 8402613
    [Abstract] [Full Text] [Related]

  • 2. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P.
    J Cell Biochem Suppl; 1996 Oct 01; 25():29-36. PubMed ID: 9027595
    [Abstract] [Full Text] [Related]

  • 3. Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.
    McCormick DL, Rao KV, Dooley L, Steele VE, Lubet RA, Kelloff GJ, Bosland MC.
    Cancer Res; 1998 Aug 01; 58(15):3282-8. PubMed ID: 9699656
    [Abstract] [Full Text] [Related]

  • 4. Experimental oncogene induced prostate cancer.
    Thompson TC, Kadmon D, Timme TL, Merz VW, Egawa S, Krebs T, Scardino PT, Park SH.
    Cancer Surv; 1991 Aug 01; 11():55-71. PubMed ID: 1726789
    [Abstract] [Full Text] [Related]

  • 5. Cholecalciferol (vitamin D3) and the retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) are synergistic for chemoprevention of prostate cancer.
    Tokar EJ, Ancrile BB, Ablin RJ, Webber MM.
    J Exp Ther Oncol; 2006 Aug 01; 5(4):323-33. PubMed ID: 17024972
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of prostate cancer in the rat with the synthetic retinoid fenretinide.
    Pienta KJ, Nguyen NM, Lehr JE.
    Cancer Res; 1993 Jan 15; 53(2):224-6. PubMed ID: 7678070
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacious chemoprevention of primary prostate cancer by flutamide in an autochthonous transgenic model.
    Raghow S, Kuliyev E, Steakley M, Greenberg N, Steiner MS.
    Cancer Res; 2000 Aug 01; 60(15):4093-7. PubMed ID: 10945615
    [Abstract] [Full Text] [Related]

  • 13. N-(4-hydroxyphenyl)retinamide prevents development of T-lymphomas in AKR/J mice.
    Chan LN, Zhang S, Cloyd M, Chan TS.
    Anticancer Res; 1997 Aug 01; 17(1A):499-503. PubMed ID: 9066702
    [Abstract] [Full Text] [Related]

  • 14. Retinoid metabolism in the prostate: effects of administration of the synthetic retinoid N-(4-hydroxyphenyl)retinamide.
    Lewis KC, Hochadel JF.
    Cancer Res; 1999 Dec 01; 59(23):5947-55. PubMed ID: 10606240
    [Abstract] [Full Text] [Related]

  • 15. Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice.
    Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM, Mukhtar H.
    Cancer Res; 2000 Sep 15; 60(18):5125-33. PubMed ID: 11016639
    [Abstract] [Full Text] [Related]

  • 16. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H, Cheepala S, McCauley E, Coombes K, Xiao L, Fischer SM, Clifford JL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [Abstract] [Full Text] [Related]

  • 17. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R, Pensa F, Orengo MA, Catsafados E, Ponzani P, Boccardo F, Costa A, Decensi A.
    Cancer Res; 1993 Oct 15; 53(20):4769-71. PubMed ID: 8402658
    [Abstract] [Full Text] [Related]

  • 18. Dietary agents in the chemoprevention of prostate cancer.
    Shukla S, Gupta S.
    Nutr Cancer; 2005 Oct 15; 53(1):18-32. PubMed ID: 16351503
    [Abstract] [Full Text] [Related]

  • 19. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
    Lee SO, Yeon Chun J, Nadiminty N, Trump DL, Ip C, Dong Y, Gao AC.
    Prostate; 2006 Jul 01; 66(10):1070-5. PubMed ID: 16637076
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.